PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells
Received date: 2019-12-31
Revised date: 2020-02-12
Online published: 2020-02-27
Supported by
Supported by the National Natural Science Foundation of China No(81520108023);CAMS Innovation Fund for Medical Sciences Nos(2019-I2M-1-003);CAMS Innovation Fund for Medical Sciences Nos(2016-I2M-3-007);Beijing Nova Program No(Z171100001117017)
Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide. Plasminogen activator inhibitor-1 (PAI-1), encoded by SERPINE1, is highly expressed in various types of tumor tissues, which contributes to cancer progression. The present study explored the role and underlying mechanisms of PAI-1 in ESCC. We found that the PAI-1 protein was extracellularly secreted more from ESCC cells with high PAI-1 expression using Western blotting and enzyme linked immunosorbent assay (ELISA). Knockdown of SERPINE1 expression significantly inhibited the invasion and migration of ESCC KYSE150 and KYSE450 cell lines, which could be restored when adding exogenous human recombinant PAI-1 into the culture medium of the cells stably expressing SERPINE1 shRNA. In vivo experiments showed that SERPINE1 knockdown significantly inhibited xenograft growth and lung metastasis of ESCC cells. Molecular analysis demonstrated that PAI-1 activated AKT and ERK signaling pathways. Co-immunoprecipitation (Co-IP) assays identified that PAI-1 may interact with the membrane receptor LDL receptor related protein 1 (LRP1). These results indicated that overexpression of PAI-1, through interacting with LRP1, might enhance invasion and migration of ESCC cells as well as promote ESCC progression.
Di Wang, Liyan Yang, Zou Liu, Jing Yu, Minjie Zhang, Yu Zhang, Yan Cai, Xin Xu, Jiajie Hao, Mingrong Wang . PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells[J]. Hereditas(Beijing), 2020 , 42(3) : 287 -295 . DOI: 10.16288/j.yczz.19-334
| [1] | Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, Jemal A, Yu XQ, He J . Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-132. |
| [2] | Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin, 2015,65(2):87-108. |
| [3] | McMahon B, Kwaan HC . The plasminogen activator system and cancer. Pathophysiol Haemost Thromb, 2008,36(3-4):184-194. |
| [4] | Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ . PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res, 2014,12(3):322-334. |
| [5] | Xu J, Zhang WW, Tang L, Chen WW, Guan XX . Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients. Gene, 2018,670:7-14. |
| [6] | Zhang WW, Xu J, Fang HH, Tang L, Chen WW, Sun Q, Zhang Q, Yang F, Sun ZJ, Cao LL, Wang YC, Guan XX . Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling. FASEB J, 2018,32(1):276-288. |
| [7] | Lin X, Lin BW, Chen XL, Zhang BL, Xiao XJ, Shi JS, Lin JD, Chen X . PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer. Biochem Biophys Res Commun, 2017,493(4):1464-1470. |
| [8] | Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD . Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci, 2012,103(2):228-232. |
| [9] | Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A . Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res, 2004,10(4):1375-1378. |
| [10] | Placencio VR, DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res, 2015,75(15):2969-2974. |
| [11] | Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, DeClerck YA. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep, 2018, 25(8): 2177-2191.e7. |
| [12] | Wang CL, Hao JJ, Wu LF, Pan BQ, Xu X, Cai Y, Wang MR, Jia XM . IGHMBP2 overexpression promotes cell migration and invasion in esophageal squamous carcinoma. Hereditas (Beijing), 2015,37(4):360-366. |
| [12] | 王春丽, 郝佳洁, 吴李飞, 潘蓓青, 徐昕, 蔡岩, 王明荣, 贾雪梅 . IGHMBP2过表达促进食管鳞癌细胞的侵袭和迁移. 遗传, 2015,37(4):360-366. |
| [13] | Liu Z, Yu SB, Ye ST, Shen ZM, Gao L, Han ZY, Zhang PP, Luo F, Chen S, Kang MQ . Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J Proteomics, 2020,211:103557. |
| [14] | Ma S, Lu CC, Yang LY, Wang JJ, Wang BS, Cai HQ, Hao JJ, Xu X, Cai Y, Zhang Y, Wang MR . ANXA2 promotes esophageal cancer progression by activating MYC- HIF1A-VEGF axis. J Exp Clin Cancer Res, 2018,37(1):183. |
| [15] | Dellas C, Loskutoff DJ . Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost, 2005,93(4):631-640. |
| [16] | Peng Y, Kajiyama H, Yuan H, Nakamura K, Yoshihara M, Yokoi A, Fujikake K, Yasui H, Yoshikawa N, Suzuki S, Senga T, Shibata K, Kikkawa F . PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor- promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Lett, 2019,442:181-192. |
| [17] | Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F . Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res, 2014,34(3):1153-1161. |
| [18] | Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del Monte G, Guadagni F, Roselli M . Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res, 2009,124(4):403-408. |
| [19] | Che Y, Wang JN, Li Y, Lu ZL, Huang JB, Sun SG, Mao SS, Lei YY, Zang RC, Sun N, He J . Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death Dis, 2018,9(7):759. |
| [20] | Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N . Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J Cell Mol Med, 2019,23(4):2984-2994. |
| [21] | Fang HH, Jin J, Huang DD, Yang F, Guan XX . PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. Cancer Sci, 2018,109(6):1949-1957. |
| [22] | Inoue M, Sawada T, Uchima Y, Kimura K, Nishihara T, Tanaka H, Yashiro M, Yamada N, Ohira M, Hirakawa K . Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep, 2005,14(6):1445-1451. |
| [23] | Geis T, D?ring C, Popp R, Grossmann N, Fleming I, Hansmann ML, Dehne N, Brüne B . HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. Exp Cell Res, 2015,331(1):46-57. |
| [24] | Mashiko S, Kitatani K, Toyoshima M, Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata T, Yaegashi N . Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther, 2015,16(2):253-260. |
| [25] | Pavón MA, Arroyo-Solera I, Téllez-Gabriel M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R . Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget, 2015,6(30):29016-29033. |
| [26] | Humphries BA, Buschhaus JM, Chen YC, Haley HR, Qyli T, Chiang B, Shen N, Rajendran S, Cutter A, Cheng YH, Chen YT, Cong J, Spinosa PC, Yoon E, Luker KE, Luker GD . Plasminogen Activator Inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer. Mol Cancer Res, 2019. 17(5):1142-1154. |
| [27] | Herz J, Strickland DK . LRP: a multifunctional scavenger and signaling receptor. J Clin Invest, 2001,108(6):779-784. |
| [28] | Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q . Role of blood-brain barrier in Alzheimer's disease. J Alzheimers Dis, 2018,63(4):1223-1234. |
| [29] | Shinohara M, Tachibana M, Kanekiyo T, Bu G . Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res, 2017,58(7):1267-1281. |
| [30] | Holtzman DM, Herz J, Bu GJ . Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2012,2(3):a006312. |
| [31] | Gheysarzadeh A, Ansari A, Emami MH, Razavi AE, Mofid MR . Over-expression of low-density lipoprotein receptor- related Protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma. Pancreatology, 2019,19(3):429-435. |
| [32] | Feng CC, Ding GX, Ding Q, Wen H . Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma. Biochem Biophys Res Commun, 2018,503(3):1537-1543. |
| [33] | Tian Y, Wang C, Chen S, Liu J, Fu Y, Luo Y . Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1. J Cell Sci, 2019,132(15). |
| [34] | Salama Y, Lin SY, Dhahri D, Hattori K, Heissig B . The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. FASEB J, 2019,33(3):3465-3480. |
/
| 〈 |
|
〉 |
www.chinagene.cn
备案号：京ICP备09063187号
